{"publication_id":"ea8f0afd-dc89-418d-b158-6e496c6cfe3b","content_hash":"sha256:976f749af7bbd40f413b362d35e78f40442ff56701a44a37f97bbb6e1be30be7","nodes":[{"id":"ea8f0afd-dc89-418d-b158-6e496c6cfe3b","type":"publication","title":"dapagliflozin: one bounded, context-dependent signal across receipts"},{"id":"claim_1","type":"claim","text":"Across retrieved fact-level receipts for dapagliflozin, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?"},{"id":"claim_2","type":"claim","text":"Finding: Dapagliflozin reduced the risk of death from cardiovascular causes (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76-0.97; P = 0.01)"},{"id":"claim_3","type":"claim","text":"This receipt-backed scoping note has one bounded signal: dapagliflozin shows context-dependent, not uniformly convergent associations across this 5-source primary/review bundle (2020-2024). Grouped by direction, directionally favorable: 3 receipt(s) | comparator/not favorable: 1 receipt(s) | economic/context only: 1 receipt(s). The source facts cover 5 population context(s) and 3 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. Concrete source-level examples: hazard ratio, 0.74 [95% CI, 0.58–0.92]; Dapagliflozin reduced the risk of death from cardiovascular causes (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76-0.97; P = 0.01); The hazard ratio (95% CI) for the primary end point in patients with chronic kidney disease was 0.71 (0.59–0.86)."},{"id":"claim_4","type":"claim","text":"null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable."},{"id":"claim_5","type":"claim","text":"directionally favorable: Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER — Dapagliflozin reduced the risk of death from cardiovascular causes (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76-0.97; P = 0.01)"},{"id":"claim_6","type":"claim","text":"Specific moderators in this bundle are population/indication (iron-deficient patients with heart failure; patients with heart failure; patients with heart failure with reduced ejection fraction; patients with heart failure with reduced ejection fraction and chronic kidney disease (eGFR <60 mL/min/1.73m²); patients with type 2 diabetes with features of SIDD or SIRD), study design/evidence type (primary/review). Single primary-study estimates are separated from pooled review or meta-analytic estimates rather than treated as interchangeable."},{"id":"claim_7","type":"claim","text":"The selected receipts group because each carries a fact-level extraction for dapagliflozin; they separate by context (human clinical/observational) and endpoint, so they are not interchangeable evidence for one pooled claim."},{"id":"claim_8","type":"claim","text":"The signal is purely descriptive of effect-direction heterogeneity; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate."},{"id":"source_1","type":"source","study":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF","year":2022,"doi":"10.1161/circulationaha.122.060511","url":"https://doi.org/10.1161/circulationaha.122.060511","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","year":2022,"doi":"10.1038/s41591-022-01971-4","url":"https://doi.org/10.1038/s41591-022-01971-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_3","type":"source","study":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction","year":2020,"doi":"10.1161/circulationaha.120.050391","url":"https://doi.org/10.1161/circulationaha.120.050391","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF","year":2020,"doi":"10.1002/ejhf.1978","url":"https://doi.org/10.1002/ejhf.1978","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology","year":2024,"doi":"10.1038/s42255-023-00943-3","url":"https://doi.org/10.1038/s42255-023-00943-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"}],"edges":[{"from":"ea8f0afd-dc89-418d-b158-6e496c6cfe3b","to":"claim_1","type":"contains_claim"},{"from":"ea8f0afd-dc89-418d-b158-6e496c6cfe3b","to":"claim_2","type":"contains_claim"},{"from":"ea8f0afd-dc89-418d-b158-6e496c6cfe3b","to":"claim_3","type":"contains_claim"},{"from":"ea8f0afd-dc89-418d-b158-6e496c6cfe3b","to":"claim_4","type":"contains_claim"},{"from":"ea8f0afd-dc89-418d-b158-6e496c6cfe3b","to":"claim_5","type":"contains_claim"},{"from":"ea8f0afd-dc89-418d-b158-6e496c6cfe3b","to":"claim_6","type":"contains_claim"},{"from":"ea8f0afd-dc89-418d-b158-6e496c6cfe3b","to":"claim_7","type":"contains_claim"},{"from":"ea8f0afd-dc89-418d-b158-6e496c6cfe3b","to":"claim_8","type":"contains_claim"}],"screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}